Issue link: https://viewer.e-digitaledition.com/i/1049957
Study Findings Enhance Precision Treatment of Breast Cancer THE NEWYORK-PRESBYTERIAN LAWRENCE HOSPITAL CANCER CENTER has incorporated recent findings from the Trial Assigning Individualized Options for Treatment (Rx), or TAILORx, study to ensure women with early-stage estrogen-receptor-positive, HER2-negative breast cancer receive effective, evidence-based treatment without undue risk of significant side effects. The study found many of these patients can forgo chemotherapy in favor of hormonal therapy. "Utilizing the results of the TAILORx study to counsel our patients and help them make decisions if they meet criteria for Oncotype DX testing is one example of the way our Cancer Center specialists can more precisely recommend treatment," says Carolyn Wasserheit, MD, medical oncologist, Director of Breast and Gynecologic Projects and Associate Director of the Breast Disease Management Team at NYP Lawrence, and Assistant Professor of Medicine at Columbia University Medical Center. The Oncotype DX testing looks at 21 genes from the tumor cells and generates a recurrence score (RS) based on the specific genes in a particular tumor. Patients with a RS from 0–10 already routinely receive hormonal therapy but not chemotherapy after a tumor is removed. Patients with scores above 25, who are at higher risk of cancer recurrence, almost always receive both. However, it has been more challenging to determine whether individuals with a RS from 11–25 should receive chemotherapy, according to Dr. Wasserheit. The TAILORx study helped clarif y that issue. Women who had a RS from 11–25 and under went hormonal therapy alone had a five-year rate of invasive-disease- free sur vival of 92.8 percent, compared with 93.1 percent for those undergoing hormone therapy plus chemotherapy. That is a statistically insignificant difference, according to the National Cancer Institute. "If I see a patient who has a breast tumor with a RS of 20, I can tell her with confidence, you don't need chemotherapy; hormonal therapy alone is just as effective," Dr. Wasserheit says. "These patients can avoid toxic chemotherapy." As Associate Director of the Breast Disease Management team, Carolyn Wasserheit, MD, works with many members of the Cancer Center team to coordinate care plans for patients before, during and after treatment. EVIDENCE-BASED APPROACHES Precision medicine permits personalized treatments for a range of cancer types — ovarian, skin, colorectal, lung and breast, to name just a few. In each case, the best management of each patient's cancer is determined by that individual's tumor characteristics. In breast cancer cases, for example, clinicians first determine i f t u mors a re hor mone-receptor-positive (H R-positive). About 70 percent of breast cancers are HR-positive, according to the A merican Ca ncer Society. Tumors can be estrogen- receptor-positive (ER-positive), progesterone-receptor-positive (PR-positive) or both. Recently relea sed results from the multinationa l Tria l Assigning Individualized Options for Treatment (Rx) (TAILORx) study illustrate how such personalized analysis can result in individualized modifications to treatment plans for people with certain types of cancer. As illustrated in TAILORx, oncologists now know that among women with HR-positive, human epidermal growth factor receptor 2-negative (HER2-negative) cancers, 70 percent of lymph node-negative patients do not require chemotherapy and instead respond equally well to hormonal therapy alone after surgery. "There are patients who come in with some knowledge about what treatments are available, perhaps wondering why they aren't getting a therapy they read about on the internet or learned of from a family member or colleague," says Carolyn Wasserheit, MD, medical oncologist, Director of Breast and Gynecologic Projects and Associate Director of the Breast Disease Management Team at NYP Lawrence, and Assistant Professor of Medicine at CUMC. Sharing the latest research with newly diagnosed, early-stage patients and informing them about the results of their individualized tumor characteristics, and, if applicable, available genetic profiling of their tumor are important parts of a consultation. A significant number of patients can be spared from receiving chemotherapy and still have confidence that less-taxing treatments have a similar likelihood of preventing recurrence, Dr. Wasserheit notes. "I explain that not every breast cancer is the same," she says. "If your friend is getting a specific therapy, it might be that their situation is different; you're your own unique person." M D N E W S . C O M /// M D N E W S L O W E R H u D S O N / B R O N x ■ 2 018 0 7

